The largest ever conducted population-based study, involving almost 130,000 patients in the Netherlands, found that breast-conserving surgery plus rad...
The largest randomized coronary stent trial in history, with >9,000 CAD patients underwent PCI enrolled, has found no difference between contempora...
The addition of N-acetylcysteine (NAC) to glyceryl trinitrate (GTN) appears to significantly reduce the infarct size by nearly one-third and increase ...
Semaglutide, a glucagon-like peptide (GLP)-1 agonist developed by Novo Nordisk, has demonstrated non-inferiority in cardiovascular (CV) risk, in fact,...
The unprecedented, 10-year, head-to-head trial to compare the effectiveness of active monitoring, surgery and radiotherapy in localized prostate cance...
In hormone receptor (HR)-positive, early breast cancer, the use of aromatase inhibitor (AI) is limited to five years only owing to the lack of efficac...
Immunotherapy with anti-PD-1 antibodies, Pembrolizumab (Keytruda, Merck & Co), was found to be superior to platinum-based doublet chemotherapy, th...
In just a week of time, a CD38 monoclonal antibody–daratumumab (Darzalex, Janssen)- has been reported twice to markedly reduce disease progression b...
The detailed findings of the study was presented on 5-June in 2016, by the lead investigator Alan P Venook, MD, professor of medicine at the Universit...
EMPA-REG OUTCOME trial was the first positive FDA-mandated cardiovascular (CV) outcome study for anti-hyperglycemia medicine reported last fall.1 Yet,...